IPMK: A Potential Drug Target and Biomarker (G253430)

Target Name: IPMK

NCBI ID: G253430

IPMK

IPMK: A Potential Drug Target and Biomarker

Intellectual property (IP) is a major concern for both individuals and companies. IPMK (IPMK_HUMAN), a protein that is expressed in human tissues, has been identified as a potential drug target and biomarker. This article will explore IPMK and its potential applications as a drug target and biomarker.

IPMK: A Potential Drug Target

IPMK is a 21-kDa protein that is expressed in various human tissues, including brain, heart, liver, and pancreas. It is a member of the Integrin伪6 subfamily and is involved in cell adhesion, migration, and invasion. IPMK has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the key features of IPMK is its ability to interact with various signaling pathways, including TGF-β, NF-kappa-B, and PI3K/AKT. These signaling pathways are involved in various cellular processes, including cell growth, differentiation, and survival. By interacting with these signaling pathways, IPMK has been shown to promote the growth and survival of various cancer cells and contribute to the development of neurodegenerative diseases.

IPMK has also been shown to play a role in the regulation of cellular immune responses. It has been shown to interact with various immune cell types, including T cells and NK cells, and has been shown to contribute to the regulation of immune cell function.

IPMK as a Biomarker

IPMK has also been shown to be a potential biomarker for various diseases. For example, IPMK has been shown to be expressed in various types of cancer, including breast, lung, and ovarian cancer. This suggests that IPMK may be a useful biomarker for the diagnosis and treatment of these diseases.

In addition to its potential as a drug target, IPMK has also been shown to be a potential biomarker for various other diseases. For example, IPMK has been shown to be expressed in individuals with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that IPMK may be a useful biomarker for the diagnosis and treatment of these diseases.

IPMK as a Potential therapeutic Approach

The potential therapeutic approach for IPMK is currently being investigated for various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

In the context of cancer, IPMK has been shown to be a potential drug target by promoting the growth and survival of cancer cells. By targeting IPMK with small molecules or antibodies, it may be possible to inhibit its function and reduce the growth of cancer cells.

In the context of neurodegenerative diseases, IPMK has been shown to be involved in the regulation of cellular immune responses. By targeting IPMK with small molecules or antibodies, it may be possible to regulate its function and improve immune cell function in individuals with neurodegenerative diseases.

In the context of autoimmune diseases, IPMK has been shown to play a role in the regulation of cellular immune responses. By targeting IPMK with small molecules or antibodies, it may be possible to regulate its function and improve immune cell function in individuals with autoimmune diseases.

Conclusion

In conclusion, IPMK is a protein that is expressed in various human tissues and has been shown to play a role in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. Its potential therapeutic approach is currently being investigated for these diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. By targeting IPMK with small molecules or antibodies, it may be possible to inhibit its function and improve treatment outcomes for these diseases.

Protein Name: Inositol Polyphosphate Multikinase

Functions: Inositol phosphate kinase with a broad substrate specificity (PubMed:12027805, PubMed:12223481, PubMed:28882892, PubMed:30420721, PubMed:30624931). Phosphorylates inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) first to inositol 1,3,4,5-tetrakisphosphate and then to inositol 1,3,4,5,6-pentakisphosphate (Ins(1,3,4,5,6)P5) (PubMed:12027805, PubMed:12223481, PubMed:28882892, PubMed:30624931). Phosphorylates inositol 1,3,4,6-tetrakisphosphate (Ins(1,3,4,6)P4) (PubMed:12223481). Phosphorylates glycero-3-phospho-1D-myo-inositol 4,5-bisphosphate to glycero-3-phospho-1D-myo-inositol 3,4,5-trisphosphate (PubMed:30420721, PubMed:28882892). Plays an important role in MLKL-mediated necroptosis via its role in the biosynthesis of inositol pentakisphosphate (InsP5) and inositol hexakisphosphate (InsP6). Binding of these highly phosphorylated inositol phosphates to MLKL mediates the release of an N-terminal auto-inhibitory region, leading to activation of the kinase. Essential for activated phospho-MLKL to oligomerize and localize to the cell membrane during necroptosis (PubMed:29883610). Required for normal embryonic development, probably via its role in the biosynthesis of inositol 1,3,4,5,6-pentakisphosphate (Ins(1,3,4,5,6)P5) and inositol hexakisphosphate (InsP6) (By similarity)

The "IPMK Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IPMK comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets